JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

GENES AND IMMUNITY, published by SpringerNature, is a leading scholarly journal dedicated to advancing the field of genetics and immunology. With an impressive impact factor and a distinguished ranking in the Q1 quartile of both Genetics and Immunology disciplines for 2023, this journal serves as a pivotal platform for researchers and professionals looking to explore the intricate relationships between genetic factors and immune responses. Established in 1999 and continuously published until 2024, it features high-quality peer-reviewed research articles, reviews, and commentary that address critical issues and recent advancements in the field. The journal adheres to rigorous academic standards, evidenced by its strong Scopus rankings, making it a valuable resource for students, researchers, and practitioners alike who are seeking to deepen their understanding of genetics' role in immunity. For those looking to keep abreast of cutting-edge insights, GENES AND IMMUNITY is an essential read.

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, published by Mary Ann Liebert, Inc, stands out as a pivotal resource in the fields of immunology, virology, and cell biology, providing comprehensive insights into cytokine functions and their roles in immune responses. With ISSN 1079-9907 and E-ISSN 1557-7465, the journal aims to disseminate innovative research that advances our understanding of interferon and cytokine biology, a crucial aspect for developing therapeutic strategies against various diseases. Covering a broad scope of research from 1995 to 2024, it boasts a respectable impact factor within its category quartiles, ranking Q2 in Medicine (miscellaneous) and Q3 in the domains of Cell Biology, Immunology, and Virology as of 2023. While it does not provide open access options, the journal remains essential for academics, researchers, and professionals dedicated to exploring the complexities of immune signaling pathways and their implications for health and disease. The journal’s consistent contribution to scientific discourse underscores its importance in elevating query-driven studies to foster advancements in biomedical science.

Immune Network is a prestigious journal dedicated to disseminating high-quality research in the field of immunology, infectious diseases, and allergy, under the esteemed KOREA ASSOCIATION OF IMMUNOLOGISTS. Founded in 2016, this journal has quickly ascended to a top-tier publication, achieving Q1 rankings in 2023 in multiple relevant categories, including Immunology, Allergy, and Infectious Diseases. With a strong emphasis on innovation and interdisciplinary research, Immune Network appeals to a diverse audience of researchers, professionals, and students keen on advancing the understanding of immune responses and disease mechanisms. However, it is crucial to note that the journal operates under a subscription model without open-access provisions. Its impact factor further solidifies its reputation, reflecting the significant influence of the articles published. Located in South Korea, the journal serves as a global platform for sharing revolutionary insights and fostering collaborations within the immunology community.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.